[go: up one dir, main page]

WO1999043815A3 - Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof - Google Patents

Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof Download PDF

Info

Publication number
WO1999043815A3
WO1999043815A3 PCT/CA1999/000178 CA9900178W WO9943815A3 WO 1999043815 A3 WO1999043815 A3 WO 1999043815A3 CA 9900178 W CA9900178 W CA 9900178W WO 9943815 A3 WO9943815 A3 WO 9943815A3
Authority
WO
WIPO (PCT)
Prior art keywords
human monoclonal
recognizing
oligospecifically
methods
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000178
Other languages
French (fr)
Other versions
WO1999043815A2 (en
Inventor
Michael E Mcknight
Mark C Glassy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Novopharm Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novopharm Biotech Inc filed Critical Novopharm Biotech Inc
Priority to AU32427/99A priority Critical patent/AU3242799A/en
Priority to CA002322003A priority patent/CA2322003A1/en
Priority to EP99936093A priority patent/EP1056861A2/en
Publication of WO1999043815A2 publication Critical patent/WO1999043815A2/en
Publication of WO1999043815A3 publication Critical patent/WO1999043815A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A human monoclonal antibody capable of recognizing major tumor-associated gangliosides was isolated, sequenced and characterized. The human monoclonal antibody and antigen binding fragments therein are useful for detecting tumor associated antigens, diagnosis of cancer cells expressing the antigens, and for therapeutic treatment of cancers.
PCT/CA1999/000178 1998-02-27 1999-02-26 Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof Ceased WO1999043815A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU32427/99A AU3242799A (en) 1998-02-27 1999-02-26 Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
CA002322003A CA2322003A1 (en) 1998-02-27 1999-02-26 Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
EP99936093A EP1056861A2 (en) 1998-02-27 1999-02-26 Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7620098P 1998-02-27 1998-02-27
US60/076,200 1998-02-27

Publications (2)

Publication Number Publication Date
WO1999043815A2 WO1999043815A2 (en) 1999-09-02
WO1999043815A3 true WO1999043815A3 (en) 1999-11-25

Family

ID=22130549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000178 Ceased WO1999043815A2 (en) 1998-02-27 1999-02-26 Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1056861A2 (en)
AU (1) AU3242799A (en)
CA (1) CA2322003A1 (en)
WO (1) WO1999043815A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384487A4 (en) * 2001-03-29 2007-07-11 Kyowa Hakko Kogyo Kk MEDICINAL PRODUCT WITH A GENETICALLY MODIFIED ANTIBODY AGAINST GANGLIOSID GD3
WO2004024874A2 (en) 2002-09-11 2004-03-25 Shantha West, Inc. Antibodies that recognize hyperproliferative cells and methods of making and using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480440A1 (en) * 1990-10-11 1992-04-15 Roche Diagnostics GmbH Monoclonal antibody against melanoma
EP0492409A1 (en) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Human monoclonal antibody
WO1994019457A1 (en) * 1993-02-26 1994-09-01 The Regents Of The University Of California Human b-lymphoblastoid cell line secreting anti-ganglioside antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480440A1 (en) * 1990-10-11 1992-04-15 Roche Diagnostics GmbH Monoclonal antibody against melanoma
EP0492409A1 (en) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Human monoclonal antibody
WO1994019457A1 (en) * 1993-02-26 1994-09-01 The Regents Of The University Of California Human b-lymphoblastoid cell line secreting anti-ganglioside antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H. YAMAGUCHI ET AL.: "Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 87, no. 9, May 1990 (1990-05-01), Washington, DC, USA, pages 3333 - 3337, XP002116959 *
K. FURUKAWA ET AL.: "Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies.", CANCER RESEARCH, vol. 49, no. 1, 1 January 1989 (1989-01-01), Baltimore, MD, USA, pages 191 - 196, XP000608629 *
M. ALFONSO ET AL.: "Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.", ACTA ONCOLOGICA, vol. 35, no. 3, 1996, Stockholm, Sweden, pages 287 - 295, XP002116960 *
S. MUKERJEE ET AL.: "Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells.", HYBRIDOMA, vol. 17, no. 2, April 1998 (1998-04-01), New York, NY, USA, pages 133 - 142, XP002116961 *
Z. ABDEL-WAHAB ET AL.: "Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.", MELANOMA RESEARCH, vol. 3, no. 6, December 1993 (1993-12-01), Oxford, GB, pages 415 - 423, XP000608631 *

Also Published As

Publication number Publication date
AU3242799A (en) 1999-09-15
EP1056861A2 (en) 2000-12-06
CA2322003A1 (en) 1999-09-02
WO1999043815A2 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
WO2004001381A3 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
MD1374G2 (en) Monoclonal immunostimulatin antibodies, method of obtaining thereof, cell lines, method of disease treatment and pharmaceutical composition
WO2004032857A3 (en) Antibody therapy
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
DE69734109D1 (en) Humanization of anti-carcinoembryonic antigen anti-idiotypic antibodies and their use as a tumor vaccine and for labeling
WO2000073801A3 (en) Breast, gastric and prostate cancer associated antigens and uses therefor
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
IE890720L (en) Improvements relating to antigens
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2002016413A3 (en) Cripto tumour polypeptide
TR200001253T2 (en) Tumor-specific antigens
IL126803A0 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO2003099205A3 (en) Treatment of renal carcinoma using antibodies against the egfr
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
EP0352722A3 (en) Adenocarcinoma antigen binding methods and reagents
AU2829889A (en) Sf-25 colon adenocarcinoma antigen, and antibodies which recognize this antigen
WO2005037999A3 (en) Treatment of cancer using antibodies to lrrc15
WO2000032635A3 (en) Tumor specific human monoclonal antibodies and methods of use
AU3556901A (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
WO1999043815A3 (en) Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
WO2001036485A3 (en) Recombinant monoclonal antibodies recognizing antigen ior c2 and the use thereof in the diagnosis and treatment of colorectal tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 32427/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2322003

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2322003

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09648624

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999936093

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999936093

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999936093

Country of ref document: EP